N-(2-(4-((4R,5S)-2-(4-(tert-butyl)-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-1-yl)-2-oxoethyl)-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-ynamide

ID: ALA4570574

PubChem CID: 155562893

Max Phase: Preclinical

Molecular Formula: C53H55Cl2N7O7

Molecular Weight: 972.97

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: CCOc1cc(C(C)(C)C)ccc1C1=N[C@H](c2ccc(Cl)cc2)[C@H](c2ccc(Cl)cc2)N1C(=O)N1CCN(C(=O)CNC(=O)CCCC#Cc2cccc3c2CN(C2CCC(=O)NC2=O)C3=O)CC1

Standard InChI: InChI=1S/C53H55Cl2N7O7/c1-5-69-43-30-36(53(2,3)4)18-23-40(43)49-58-47(34-14-19-37(54)20-15-34)48(35-16-21-38(55)22-17-35)62(49)52(68)60-28-26-59(27-29-60)46(65)31-56-44(63)13-8-6-7-10-33-11-9-12-39-41(33)32-61(51(39)67)42-24-25-45(64)57-50(42)66/h9,11-12,14-23,30,42,47-48H,5-6,8,13,24-29,31-32H2,1-4H3,(H,56,63)(H,57,64,66)/t42?,47-,48+/m1/s1

Standard InChI Key: MRDNCCKFZSDMNU-WFFJVVBASA-N

Molfile:

 
     RDKit          2D

 69 76  0  0  0  0  0  0  0  0999 V2000
   31.0650   -5.1473    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   30.2830   -5.3998    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.2826   -6.2263    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.0653   -6.4836    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   31.5507   -5.8127    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.6136   -4.9160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.7022   -4.0905    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.0320   -3.6008    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.2728   -3.9396    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.1878   -4.7686    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.8589   -5.2504    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.6146   -6.7161    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.8562   -6.3791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.1852   -6.8636    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.2714   -7.6891    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.0344   -8.0278    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.7022   -7.5371    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.6011   -3.4506    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   27.6007   -8.1793    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   32.3717   -5.8100    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.7850   -6.5253    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.6093   -6.5240    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.0211   -5.8081    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.6026   -5.0922    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.7798   -5.0970    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.3638   -4.3846    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   32.7729   -3.6681    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.3570   -2.9557    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.8460   -5.8053    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.2610   -6.5183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.2561   -5.0894    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.6698   -5.8040    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.3195   -7.2684    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.7669   -7.8810    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   32.1263   -7.4406    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   32.3751   -8.2248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.1811   -8.3972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.7346   -7.7843    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   33.4764   -6.9962    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.6711   -6.8275    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.5416   -7.9554    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.0933   -7.3421    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   34.7969   -8.7399    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.6039   -8.9110    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   36.1557   -8.2976    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.9627   -8.4688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.9004   -7.5132    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   37.5144   -7.8554    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.3214   -8.0265    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.8731   -7.4133    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.4216   -6.8020    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.9725   -6.1880    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   41.0744   -4.9612    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   40.2625   -4.7928    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.7153   -5.4074    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   41.3306   -5.7463    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   40.7825   -6.3590    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   41.1958   -7.0697    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   41.9995   -6.8963    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   42.0826   -6.0784    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   42.6112   -7.4449    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   42.4402   -8.2529    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   43.0511   -8.8021    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   43.8365   -8.5485    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   44.0075   -7.7404    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   43.3931   -7.1859    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   43.5629   -6.3786    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   42.7958   -5.6636    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   44.4493   -9.1009    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  2  3  1  0
  1  2  1  0
  3  4  1  0
  4  5  1  0
  5  1  2  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11  6  1  0
  2  6  1  1
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 12  1  0
  3 12  1  1
  9 18  1  0
 15 19  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 20  1  0
  5 20  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 23 29  1  0
 29 30  1  0
 29 31  1  0
 29 32  1  0
  4 33  1  0
 33 34  2  0
 33 35  1  0
 35 36  1  0
 36 37  1  0
 37 38  1  0
 38 39  1  0
 39 40  1  0
 40 35  1  0
 38 41  1  0
 41 42  2  0
 41 43  1  0
 43 44  1  0
 44 45  1  0
 45 46  1  0
 45 47  2  0
 46 48  1  0
 48 49  1  0
 49 50  1  0
 50 51  3  0
 51 52  1  0
 52 57  2  0
 56 53  2  0
 53 54  1  0
 54 55  2  0
 55 52  1  0
 56 57  1  0
 57 58  1  0
 58 59  1  0
 59 60  1  0
 60 56  1  0
 61 62  1  0
 61 66  1  0
 62 63  1  0
 63 64  1  0
 64 65  1  0
 65 66  1  0
 59 61  1  0
 66 67  2  0
 60 68  2  0
 64 69  2  0
M  END

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Unknown	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 972.97	Molecular Weight (Monoisotopic): 971.3540	AlogP: 7.60	#Rotatable Bonds: 11
Polar Surface Area: 161.03	Molecular Species: NEUTRAL	HBA: 8	HBD: 2
#RO5 Violations: 2	HBA (Lipinski): 14	HBD (Lipinski): 2	#RO5 Violations (Lipinski): 3
CX Acidic pKa: 11.55	CX Basic pKa: 3.84	CX LogP: 7.05	CX LogD: 7.05
Aromatic Rings: 4	Heavy Atoms: 69	QED Weighted: 0.09	Np Likeness Score: -0.31

References

1. Wang B, Wu S, Liu J, Yang K, Xie H, Tang W.. (2019) Development of selective small molecule MDM2 degraders based on nutlin., 176 [PMID:31128449] [10.1016/j.ejmech.2019.05.046]
2. Raboisson, Pierre P and 12 more authors. 2005-04-01 Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists. [PMID:15780621]
3. Schneekloth, Ashley R AR, Pucheault, Mathieu M, Tae, Hyun Seop HS and Crews, Craig M CM. 2008-11-15 Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. [PMID:18752944]
4. Hayashi, Ryo R and 5 more authors. 2009-12-01 N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53. [PMID:19880322]
5. Madden, Michael M and 5 more authors. 2011-03-01 Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition. [PMID:21277201]
6. Ghosh, Pradip P, Zhang, Jiawei J, Shi, Zheng-Zheng ZZ and Li, King K. 2013-04-15 Synthesis and evaluation of an imidazole derivative-fluorescein conjugate. [PMID:23477941]
7. Zhao, Yujun Y and 12 more authors. 2013-07-11 A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. [PMID:23786219]
8. Blackburn, Tim J and 14 more authors. 2013-09-21 Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions†Electronic supplementary information (ESI) available: Experimental details for compound synthesis, analytical data for all compounds and intermediates. Details for the biological evaluation. Further details for the modeling. Table of combustion analysis data. See DOI: 10.1039/c3md00161jClick here for additional data file. [PMID:24078862]
9. Li, Jin J and 14 more authors. 2014-06-15 Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy. [PMID:24813735]
10. Zheng, Guang-hui GH and 7 more authors. 2014-06-23 Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction. [PMID:24852275]
11. Rew, Yosup Y and 34 more authors. 2014-12-26 Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction. [PMID:25384157]
12. Zhao, Yujun Y, Aguilar, Angelo A, Bernard, Denzil D and Wang, Shaomeng S. 2015-02-12 Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. [PMID:25396320]
13. Aguilar, Angelo and 7 more authors. 2014-12-26 Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles. [PMID:25496041]
14. Neochoritis, Constantinos G and 8 more authors. 2015-12-15 2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists. [PMID:26584879]
15. Daniele, Simona S and 12 more authors. 2016-05-26 Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas. [PMID:27050782]
16. Aguilar, Angelo and 17 more authors. 2017-04-13 Discovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development. [PMID:28339198]
17. Giustiniano, Mariateresa M and 18 more authors. 2017-10-12 Computer-Aided Identification and Lead Optimization of Dual Murine Double Minute 2 and 4 Binders: Structure-Activity Relationship Studies and Pharmacological Activity. [PMID:28921985]
18. Merlino, Francesco F and 20 more authors. 2018-06-14 Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme. [PMID:29775303]
19. Niazi, Sarfaraj S, Purohit, Madhusudan M and Niazi, Javed H JH. 2018-10-05 Role of p53 circuitry in tumorigenesis: A brief review. [PMID:30199707]
20. Wang, Bo B and 5 more authors. 2019-08-15 Development of selective small molecule MDM2 degraders based on nutlin. [PMID:31128449]
21. Sang, Peng and 10 more authors. 2020-02-13 α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53-MDM2/MDMX Protein-Protein Interactions. [PMID:31971801]

N-(2-(4-((4R,5S)-2-(4-(tert-butyl)-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-1-yl)-2-oxoethyl)-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-ynamide

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source